Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0N4EO
|
|||
Former ID |
DIB002179
|
|||
Drug Name |
GMI-1070
|
|||
Synonyms |
GMI-1010; GMI-1011; GMI-1040 series; GMI-1077; Glyosin, GlycoMimetics; Heterobifunctional glycomimetic pan-selectin inhibitors (smallmolecule therapeutic), GlycoMimetics; Selectin inhibitors (asthma/sickle cell anemia/hematological neoplasm), GlycoMimetics
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 3 | [1], [2], [3] | |
Vaso-occlusive crisis [ICD-11: BE2Y; ICD-10: D57.00; ICD-9: 282.62] | Phase 3 | [4] | ||
Company |
Glycomimetics; pfizer
|
|||
Structure |
Download2D MOL |
|||
Formula |
C58H74N6O31S3
|
|||
Canonical SMILES |
CC1C(C(C(C(O1)OC2C(CC(CC2OC3C(C(C(C(O3)CO)O)OC(CC4CCCCC4)C(=O)O)OC(=O)C5=CC=CC=C5)C(=O)NCCNC(=O)COCCOCC(=O)NC6=C7C(=CC(=C6)S(=O)(=O)O)C=C(C=C7S(=O)(=O)O)S(=O)(=O)O)NC(=O)C8=CC(=O)NC(=O)N8)O)O)O
|
|||
InChI |
1S/C58H74N6O31S3/c1-27-45(69)47(71)48(72)56(90-27)95-49-35(62-53(74)36-23-41(66)64-58(78)63-36)19-31(20-37(49)92-57-51(94-55(77)29-10-6-3-7-11-29)50(46(70)39(24-65)93-57)91-38(54(75)76)16-28-8-4-2-5-9-28)52(73)60-13-12-59-42(67)25-88-14-15-89-26-43(68)61-34-21-32(96(79,80)81)17-30-18-33(97(82,83)84)22-40(44(30)34)98(85,86)87/h3,6-7,10-11,17-18,21-23,27-28,31,35,37-39,45-51,56-57,65,69-72H,2,4-5,8-9,12-16,19-20,24-26H2,1H3,(H,59,67)(H,60,73)(H,61,68)(H,62,74)(H,75,76)(H,79,80,81)(H,82,83,84)(H,85,86,87)(H2,63,64,66,78)/t27-,31+,35-,37+,38-,39+,45+,46-,47+,48-,49+,50-,51+,56-,57+/m0/s1
|
|||
InChIKey |
VXBNTHRZPJLRSS-PTCSXESPSA-N
|
|||
CAS Number |
CAS 927881-99-0
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8307). | |||
REF 2 | Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890. | |||
REF 3 | GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood. 2010 Sep 9;116(10):1779-86. | |||
REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 5 | GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood. 2010 September 9; 116(10): 1779-1786. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.